Methenamine Hippurate
Composition
Methebac Tablet: Each tablet contains Methenamine Hippurate USP 1 g.
Indications
Methebac is indicated for prophylactic or suppressive treatment of
frequently recurring urinary tract infections when long-term therapy is
considered necessary. This drug should only be used after eradication
of the infection by other appropriate antimicrobial agents.
Dosage & Administration
1 tablet (1.0 g) twice daily (morning and night) for adults and paediatric
patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1.0 g) twice daily
(morning and night) for paediatric patients 6 to 12 years of age. Since the
antibacterial activity of Methebac is greater in acid urine, restriction of
alkalinizing foods and medications is desirable or as directed by the
physician
Pimecrolimus
Composition
Pmec Cream: Each gram cream contains Pimecrolimus INN 10 mg.
Pharmacology
The mechanism of action of Pimecrolimus in atopic dermatitis is not known. It has
been demonstrated that Pimecrolimus binds with macrophilin-12 (FKBP-12) and
inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it
inhibits T cell activation. In particular, Pimecrolimus inhibits Interleukin-2 and
Interferon gamma (Th1-type), Interleukin-4 and Interleukin-10 (Th2-type) cytokine
synthesis in human T cells. In addition, Pimecrolimus prevents the release of
inflammatory cytokines and mediators from mast cells in vitro after stimulation by
antigen/IgE.
Indication
Pmec Cream is indicated as second-line therapy for the short-term and
noncontinuous chronic treatment of mild to moderate atopic dermatitis in
non-immunocompromised adults and children 2 years of age and older, who have
failed to respond adequately to other topical prescription treatments or when those
treatments are not advisable.
Route of Administration
Topical use only
Dose & Administration
Skin should be cleaned before applying the cream. One finger tip unit (measured
by distance from the tip of an adult index finger to the first crease of that finger) to
be applied thinly and evenly on the affected area of skin twice daily. (PHYSICIAN
MAY ADJUST THE DOSE). Treatment should be stopped if signs and symptoms
(e.g. itch, rash and redness) resolve. If signs and symptoms persist and beyond 6
weeks, patients should be re-examined to confirm the diagnosis of atopic
dermatitis. A patient should not use sun lamps, tanning beds, or get treatment with
ultraviolet light therapy during treatment with Pmec Cream. Continuous long-term
use of Pimecrolimus should be avoided. A patient should not cover the skin being
treated with bandages, dressings or wraps. Loose fitting clothing that protects the
treated area from the sun are encouraged.
